Next Article in Journal
A New Isoflavonoid from Seeds of Lepidium sativum L. and Its Protective Effect on Hepatotoxicity Induced by Paracetamol in Male Rats
Next Article in Special Issue
Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I
Previous Article in Journal
Editorial to the Organophosphorus Chemistry Special Issue of Molecules (2012–2014)
Previous Article in Special Issue
Design and Synthesis of C-Terminal Modified Cyclic Peptides as VEGFR1 Antagonists
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Molecules 2014, 19(10), 15411-15439; doi:10.3390/molecules191015411

Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II

1
Normandie Univ, Laboratoire C.O.B.R.A., UMR 6014 and FR 3038; Univ Rouen; INSA de Rouen; CNRS, Bâtiment I.R.C.O.F. rue Tesnière, Mont-Saint-Aignan F-76821, France
2
Diaxonhit, 65 boulevard Masséna, Paris F-75013, France
*
Author to whom correspondence should be addressed.
Received: 7 August 2014 / Revised: 15 September 2014 / Accepted: 16 September 2014 / Published: 26 September 2014
(This article belongs to the Special Issue Design and Study of Kinase Inhibitors)
View Full-Text   |   Download PDF [940 KB, uploaded 29 September 2014]   |  

Abstract

The convenient synthesis of a focused library (forty molecules) of novel 6,6,5-tricyclic thiazolo[5,4-f]quinazolines was realized mainly under microwave irradiation. A novel 6-aminobenzo[d]thiazole-2,7-dicarbonitrile (1) was used as a versatile molecular platform for the synthesis of various derivatives. Kinase inhibition, of the obtained final compounds, was evaluated on a panel of two kinases (DYRK1A/1B) together with some known reference DYRK1A and DYRK1B inhibitors (harmine, TG003, NCGC-00189310 and leucettine L41). Compound IC50 values were obtained and compared. Five of the novel thiazolo[5,4-f]quinazoline derivatives prepared, EHT 5372 (8c), EHT 6840 (8h), EHT 1610 (8i), EHT 9851 (8k) and EHT 3356 (9b) displayed single-digit nanomolar or subnanomolar IC50 values and are among the most potent DYRK1A/1B inhibitors disclosed to date. DYRK1A/1B kinases are known to be involved in the regulation of various molecular pathways associated with oncology, neurodegenerative diseases (such as Alzheimer disease, AD, or other tauopathies), genetic diseases (such as Down Syndrome, DS), as well as diseases involved in abnormal pre-mRNA splicing. The compounds described in this communication constitute a highly potent set of novel molecular probes to evaluate the biology/pharmacology of DYR1A/1B in such diseases. View Full-Text
Keywords: thiazolo[5,4-f]quinazolines; kinase inhibitors; DYRK1A; DYRK1B; microwave-assisted chemistry; Dimroth rearrangement; EHT 5372; EHT 6840; EHT 1610; EHT 9851; EHT 3356 thiazolo[5,4-f]quinazolines; kinase inhibitors; DYRK1A; DYRK1B; microwave-assisted chemistry; Dimroth rearrangement; EHT 5372; EHT 6840; EHT 1610; EHT 9851; EHT 3356
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Foucourt, A.; Hédou, D.; Dubouilh-Benard, C.; Girard, A.; Taverne, T.; Casagrande, A.-S.; Désiré, L.; Leblond, B.; Besson, T. Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II. Molecules 2014, 19, 15411-15439.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top